#USA #Dublin #Jazz Pharmaceuticals #Zanidatamab #Q1 2026

Jazz Pharmaceuticals Reports First Quarter 2026 Financials

On May 5, 2026, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) unveiled its financial results for the first quarter of the year 2026, showcasing a remarkable growth trajectory. The company achieved total revenues of $1.1 billion, marking a 19% increase compared to the same period last year. This surge in revenue reflects Jazz's focused efforts in its commercial operations and advancements in its product pipeline.

Key Highlights

The financial report detailed several key highlights:

• - Diverse Revenue Growth: The revenue boost of 19% year-over-year was attributed primarily to strong sales of Xywav, Epidiolex, and the recently launched oncology drugs, Modeyso and Zepzelca.
• - Xywav Performance: Xywav, a treatment for narcolepsy and idiopathic hypersomnia, experienced an impressive 18% year-over-year revenue growth, amounting to $408 million. The product continues to attract new patients, contributing approximately 425 new net patients this quarter.
• - Epidiolex Upsurge: Revenues from Epidiolex rose 15%, totaling $250 million. This growth was driven by a robust demand for the cannabis-derived medication, especially after the announcement of a partnership with Nippon Zoki for commercialization in Japan, pending regulatory approvals.
• - Pipeline Advancements: Notably, Jazz Pharmaceuticals also highlighted the Priority Review granted by the U.S. FDA for the supplemental Biologics License Application (sBLA) for Zanidatamab in treating HER2-positive gastroesophageal adenocarcinoma (GEA), with a target approval date of August 25, 2026. The positive Phase 3 HERIZON-GEA-01 trial results presented at the ASCO GI conference reinforce the drug’s potential.

Financial Metrics

For the first quarter of 2026, Jazz reported:

• - GAAP net income of $293.1 million, a stark recovery from a loss of $92.5 million in Q1 2025.
• - Non-GAAP adjusted net income of $419.5 million, reflecting an impressive adjusted earnings per share (EPS) of $6.34, compared to $1.68 in the previous year.

These figures indicate effective cost management and operational improvements leading to significant profitability turnaround.

Business Strategy and Future Outlook

Jazz Pharmaceuticals’ president and CEO, Renee Gala, expressed confidence in the company's trajectory, attributing this growth to disciplined execution across all business segments. With a strong pipeline centered on innovative treatments for rare diseases, the company is well-positioned to further expand its market presence. Looking ahead, Jazz maintains its guidance for total revenue in 2026 at $4.25 billion to $4.5 billion.

The company’s cash position remains robust, with approximately $2.9 billion in cash, cash equivalents, and investments, thus exhibiting financial stability to support sustained growth and development activities. Also, with the coming launch of Zanidatamab and ongoing clinical trials, Jazz Pharmaceuticals is keen to enhance the lives of patients, especially in oncology, where the landscape is continuously evolving.

Conclusion

The first quarter of 2026 has undeniably set a promising tone for Jazz Pharmaceuticals, characterized by substantial revenue growth, alongside efforts focused on innovating life-changing therapies. As the company balances its current successes with future potential, stakeholders can expect Jazz to remain a key player in the biopharmaceutical industry.

For more information about Jazz Pharmaceuticals and their innovative treatments, visit Jazz Pharmaceuticals.